[Form 4] OrthoPediatrics Corp. Insider Trading Activity
Rhea-AI Filing Summary
OrthoPediatrics Corp. (KIDS) Form 4: Chief Operating Officer and Chief Financial Officer Fred Hite purchased 5,076 shares of OrthoPediatrics common stock in the open market on 08/21/2025 at $19.41 per share, bringing his beneficial ownership to 213,065 shares including 150,360 restricted shares. The filing notes the purchase was matchable under Section 16(b) with a prior sale, and Mr. Hite disgorged $27,664.20 to the company representing the full short-swing profit.
The transaction was reported by an attorney-in-fact on 08/25/2025. The Form 4 shows direct ownership and does not report derivative transactions. No additional executive departures, changes in compensation, or forward-looking statements are included in the filing.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider bought a modest number of shares while resolving a short-swing profit with a disgorgement; impact is likely neutral to investors.
The reported open-market purchase of 5,076 shares at $19.41 is small relative to total outstanding shares and to Mr. Hite's reported 213,065 beneficially owned shares, suggesting limited economic impact on supply or demand. The noted disgorgement of $27,664.20 indicates the prior sale generated a short-swing profit that was returned to the company, which resolves a technical Section 16(b) issue but does not indicate ongoing financial distress. For investors this is a routine insider activity disclosure rather than a material corporate development.
TL;DR: Disgorgement for a Section 16(b) matchable transaction raises governance and compliance questions despite remediation.
The filing discloses that the open-market purchase was matchable with a prior sale triggering a short-swing profit under Section 16(b); Mr. Hite returned the full profit of $27,664.20. While the disgorgement closes the immediate compliance matter, it highlights a lapse in transaction timing oversight for a senior officer who serves as COO and CFO. The company should ensure stronger pre-clearance and reporting controls to prevent recurrence. This is governance-relevant but not necessarily material to operations.